Context:The concept of quality of life (QoL) is becoming an important measure of the impact of psychiatric disorders. It is natural that once patient achieves remission, QoL would improve, but very few studies are conducted under this phase. This study compares the differences in QoL in remitted patients with monotherapy and polypharmacy.Aims:The aim of this study is to compare the QoL between psychiatric patients in remission treated with monotherapy and polypharmacy.Settings and Design:It is a questionnaire based cross-sectional comparative study.Materials and Methods:This study included outpatients under remission who come for follow-up in psychiatric department. Semi-structured data collection form was used. Remission was confirmed using suitable scales, and QoL was assessed using the World Health Organization quality of life-Brief (WHOQOL-BREF) scale. Clinical Global Impression (CGI) and Global Assessment of Functioning (GAF) were applied to understand the overall improvement and functioning levels.Results:Out of the total 100 patients enrolled in the study, fifty patients were on monotherapy and fifty patients on polypharmacy. The cost of medication was comparatively high for polypharmacy (Rs. 3568.92 [±348.54]) than monotherapy (Rs. 1936.56 [±252.07]). The QoL in physical, psychological, and social domains was significantly high in patients on polypharmacy rather than monotherapy when assessed using the WHOQOL-BREF scale. Ninety-six percent of monotherapy patients had CGI scores between 1.5 and 2.4 while 74% of polypharmacy patients had scores between 1.0 and 1.5. Ninety-six percent of monotherapy patients had <80 GAF scores while 92% of polypharmacy patients had >80.Conclusions:Patients treated with polypharmacy had better QoL and also clinical improvement and functioning levels were superior.
According to the World Health Organizations' (WHO) estimates for 2002, LRTIs were the leading cause of death among all infectious diseases worldwide, accounting for 3.9 million deaths and 6.8% of all reported deaths that year. Since 1990, when the WHO began compiling and presenting statistics on the burden of lung infections, LRTIs have been found to consistently cause more burden than diseases such as diabetes mellitus, HIV/AIDS, cerebrovascular disease, neoplasms, diarrhoeal disease, ischaemic heart disease, malaria, tuberculosis, chronic obstructive pulmonary disease (COPD) and asthma. 1 Lower respiratory tract infections (LRTIs) including bronchitis (viral and bacterial),pneumonia, bronchiolitis, and pertussis (whooping cough) are among the most ABSTRACT Background: Lower respiratory tract infections are the leading cause of death among infectious diseases and responsible for large burden of avoidable morbidity and mortality in childhood. Inappropriate, economically inefficient use of antibiotics has been observed in health care system. The objective of the present study is to identify various lower respiratory tract disorders, antibiotic prescription patterns, average hospital duration and average direct cost of antibiotic prescriptions. Methods: The present study was an observational study. A total of 110 inpatients fulfilling the inclusion criteria were included. Current diagnosis, treatment chart, length of hospital stay, MRP (INR) of antibiotics on admission to discharge were recorded and analyzed. Results: Males are more as compared to females with similar severity of illness. Study states that Bronchopneumonia is highest in the incidence followed by WALRI. Average duration of patient stay in hospital was 5.71days whereas 62.73% were on monotherapy and mostly prescribed antibiotic was Cephalosporin's. Average cost of antibiotic prescription in bronchopneumonia is INR 1681.94 followed by Walri INR 579.64, bronchiolitis INR 355.68 others INR 1044.9. Majority of drugs were given by intravenous route and Prescriptions are mainly ordered in Brand names. Conclusions: The present study provides an overall pattern of antibiotic usage in patients. Higher generation antibiotic usages and brand name prescription especially in bronchiolitis & WALRI where there is no requirement, adds to the cost of the therapy.
Hair loss (alopecia) is an occasional side effect associated with psychotropic drugs use. Fluvoxamine is a synthetic antidepressant which acts as a selective serotonin reuptake inhibitor as well as sigma-1 receptor agonist. Psychotropic drugs are considered to cause hair loss by affecting the telogenic phase of hair follicle. Here we present a case of a 28 year old male patient reported with diffuse hair loss after administration of fluvoxamine and condition remitted after cessation of the drug. Our report suggests the possibility of developing alopecia with fluvoxamine use.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.